Average Insider

Where insiders trade, we follow

$ELVN
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
Healthcare
Sector
Biotechnology
Industry
Richard A. Fair
CEO
62
Employees
$48.87
Current Price
$1.55B
Market Cap
52W Low$14.79
Current$48.8771.7% above low, 28.3% below high
52W High$62.32

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys00---
Sells00--
2 weeksBuys00--All Sells
Sells26$554,756.8911,018
1 monthBuys00--All Sells
Sells26$554,756.8911,018
2 monthsBuys00--All Sells
Sells311$10,761,825.69180,831
3 monthsBuys00--All Sells
Sells423$11,846,882.65201,849
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
DateInsiderTypeSharesPriceValueActions
Jul 17, 2026
Collins Helen Louise
CHIEF MEDICAL OFFICER
Sale2,063$52.39$108,084.90View Details
Jul 6, 2026
Kunkel Lori Anne
Director
Sale4,111$49.98$205,481.76View Details
Jul 6, 2026
Kunkel Lori Anne
Director
Sale5,889$50.84$299,421.49View Details
54 more transactions available โ€” create a free account to see 12 months of history

Upcoming Earnings

Scheduled earnings reports
No upcoming earnings scheduled

Past Earnings

Historical earnings results
No earnings data in the last 3 months. Sign up free to see 12 months of history.
Version: v26.9.12